erythrosine has been researched along with picibanil in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukumura, D; Kagawa, T; Kurose, I; Miura, S; Morizane, T; Saito, H; Suematsu, M; Tada, S; Tsuchiya, M | 1 |
| Asano, T; Habu, Y; Hayakawa, M; Kuranaga, N; Satoh, K; Seki, S; Shinomiya, N; Takahashi, E | 1 |
2 other study(ies) available for erythrosine and picibanil
| Article | Year |
|---|---|
Visualization of oxidative processes at the cellular level during neutrophil-mediated cytotoxicity against a human hepatoma cell line, HCC-M.
Topics: Carcinoma, Hepatocellular; Fluoresceins; Humans; Liver Neoplasms; Luminescent Measurements; Neutrophils; Oxidation-Reduction; Picibanil; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1992 |
Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells.
Topics: Antineoplastic Agents; CD56 Antigen; Cytokines; Cytotoxicity, Immunologic; Fluoresceins; Histocompatibility Antigens Class I; Humans; Killer Cells, Natural; Leukocytes, Mononuclear; Lymphocyte Activation; Neoplasms; Picibanil; Receptors, IgG; Streptococcus pyogenes; T-Lymphocyte Subsets | 2007 |